2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating hemoglobinopathy, thalassemia, sickle cell disease and other disorders
WO2021007378A1
Compounds for use in treating huntington's disease
WO2020252414A1
Naphthoquinone derivatives for treatment of oxidative stress disorders
WO2020231977A1
Compounds for treating huntington's disease
WO2020210663A1
Dispersible tablet composition
WO2020210432A1
Method for treating nonsense mutation mediated duchenne muscular dystrophy in pediatric patients
WO2020198705A1
Combinations useful in a method for treating sarcoma
WO2020191366A1
Vector and method for treating angelman syndrome
WO2020191087A1
Therapeutic combinations for use in treating a muscular dystrophy
WO2020185648A1
Compound form having enhanced bioavailability and formulations thereof
WO2020176610A1
Method for treating a multiple myeloma
WO2020167628A1
Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1
Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia
WO2020150326A1
Method for treating an acute myeloid leukemia
WO2020081879A2
2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING α-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS
CA3109386A1
Method for treating pancreatic cancer
CA3107737A1
Bioavailable oral dosage forms
WO2020005882A1
Heteroaryl compounds for treating huntington's disease
BR112020026534A2
HETEROARILLA COMPOUNDS FOR THE TREATMENT OF HUNTINGTON'S DISEASE
AU2019294478A1
Heterocyclic and heteroaryl compounds for treating Huntington's disease
